ArticleNature communications2021
In vivo activation of pH-responsive oxidase-like graphitic nanozymes for selective killing of Helicobacter pylori.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 213 citations in OpenAlex.
- Research trends of nanomaterials inFrontiers in pharmacology · 2025Pooled it
- Use of WeChat-based patient-doctor interaction improves patient experience ofFrontiers in digital health · 2026Trial
- Biomaterial-driven remove-remodel-repair (3R) strategy for full-cycle gastric cancer management: bibliometric mapping, preclinical evidence, and a translational roadmap.Nanoscale advances · 2026Review
- Silk-based biomimetic nanocomposite for precision eradication of Helicobacter pylori and gut microbiome preservation.Journal of nanobiotechnology · 2026Article
- pH-responsive nanozymes: multifunctional platforms for biomedical catalysis toward clinical translation.Frontiers in bioengineering and biotechnology · 2026Review
- Photo-responsive nanozymes: from photocatalytic mechanisms to precision therapy.Frontiers in chemistry · 2026Review
- Antimicrobial Nanozymes: Structure-Activity-Guided Design, Synergy, and Applications.Research (Washington, D.C.) · 2026Review
- Harnessing nanozymes as next-generation antimicrobial agents: From mechanisms to therapeutic strategies.Materials today. Bio · 2025Article
- Biomedical Applications of Nanozymes: An Enzymology Perspective.Angewandte Chemie (International ed. in English) · 2025Review
- New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).International journal of molecular medicine · 2025Review
- Ferrocene-functionalized indium-oxo cluster nanozyme for the detection of hydrogen peroxide and ascorbic acid.Analytical and bioanalytical chemistry · 2025Article
- Graphene-based nanozymes for revolutionizing biomedical research.RSC advances · 2025Review
- Surface-Modified Nanozymes for Enhanced and Selective Catalysis.ACS applied materials & interfaces · 2025Review
- Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.Journal of nanobiotechnology · 2025Review
- Biomaterials mediated 3R (remove-remodel-repair) strategy: holistic management of Helicobacter pylori infection.Journal of nanobiotechnology · 2025Review
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- Inhibition of the cGAS-STING pathwayChemical science · 2025Article
- Artificial intelligence driven platform for rapid catalytic performance assessment of nanozymes.Scientific reports · 2025Article
- Selective G6PDH inactivation for Helicobacter pylori eradication with transformed polysulfide.Science China. Life sciences · 2025Article
- Nucleotide coordinated polymers, a ROS-based immunomodulatory antimicrobial, doubly killBioactive materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori infection is a major etiological factor in gastric diseases. However, clinical antibiotic therapy for H. pylori is limited by continuously decreased therapeutic efficacy and side effects to symbiotic bacteria. Herein, we develop an in vivo activatable pH-responsive graphitic nanozyme, PtCo@Graphene (PtCo@G), for selective treatment of H. pylori. Such nanozymes can resist gastric acid corrosion, exhibit oxidase-like activity to stably generate reactive oxygen species only in acidic gastric milieu and demonstrate superior selective bactericidal property. C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.